Breast Cancer
Article
Should supplemental MRI be used in otherwise average-risk women with extremely dense breasts?
Recent data show that supplemental MRI screening in women with extremely dense breasts and negative screening mammograms decreases the rate of...
News
Global project reveals cancer’s genomic playbook
The Pan-Cancer Analysis of Whole Genomes, an international collaboration, reveals the complexity of oncogenesis.
News
High-dose chemo offers survival benefit only for highest-risk breast cancer
Women with 10 or more involved axilliary nodes or triple-negative breast cancer had a 20-year overall survival benefit from high-dose chemotherapy...
Article
Researchers win funding for breast cancer studies
Five breast cancer researchers have won up to $1.4 million in funding from the National Comprehensive Cancer Network and Pfizer.
News
Score predicts locoregional recurrence of breast cancer
Postmenopausal patients with node-positive breast cancer were more likely to have locoregional recurrence if they had intermediate or high...
News
Insurance coverage mediates racial disparities in breast cancer
“Without insurance coverage, the lack of prevention, screening, and access to care, as well as delays in diagnosis, lead to later stage of disease...
Opinion
SABCS research changes practice
Dr. Alan P. Lyss reviews the studies from the San Antonio Breast Cancer Symposium that are likely to change practice immediately.
Conference Coverage
ctDNA shows clinical value in advanced breast cancer
SAN ANTONIO – The plasmaMATCH trial showed that gene level agreement between ctDNA results measured by digital PCR versus sequencing was as high...
Conference Coverage
Sensitivity of ctDNA equivalent to that of tumor tissue sequencing
SAN ANTONIO – When plasma and tumor tissue samples were taken within 60 days of one another, sensitivity of ctDNA testing was 98% for digital...
Conference Coverage
Neoadjuvant cisplatin fails to beat standard AC in HER2-negative breast cancer
SAN ANTONIO – Platinum-based chemotherapy was associated with an 18% pCR rate, compared with 26% for standard AC among newly diagnosed HER2-...